Cas:26153-26-4 2-naphthalen-1-yl-2-oxoacetic acid manufacturer & supplier

Chemical Name:2-naphthalen-1-yl-2-oxoacetic acid

CAS.NO:26153-26-4

Synonyms:Naphthalenyl oxoacetic acid;1-napthtylglyoxylic acid;1-NAPHTHOYLFORMIC ACID;1-Naphthaleneaceticacid,a-oxo;1-naphthylglyoxylic acid;1-napththylglyoxylic acid

Molecular Formula:C₁₂H₈O₃

Molecular Weight:200.19000

HS Code:2918300090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:372.4ºC at 760 mmHg

Density:1.337g/cm3

Index of Refraction:1.666

PSA:54.37000

Exact Mass:200.04700

LogP:2.10710

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Naphthalenyl oxoacetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-napththylglyoxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-napththylglyoxylic acid Use and application,1-naphthylglyoxylic acid technical grade,usp/ep/jp grade.

Related News: Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs. 2-naphthalen-1-yl-2-oxoacetic acid manufacturer The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. 2-naphthalen-1-yl-2-oxoacetic acid supplier Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. 2-naphthalen-1-yl-2-oxoacetic acid vendor The FDA has granted so-called accelerated approval in more than 250 instances since 1992, mainly for rare diseases or small patient populations that have had no effective treatments available to them. In these cases, the agency requires that drugmakers conduct additional clinical trials to prove their therapy works, or face withdrawal from the market. 2-naphthalen-1-yl-2-oxoacetic acid factory Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs.